Tissue | GTEx Coverage  | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
|---|---|---|---|---|---|---|
| ovary | 100% | 10243.25 | 180 / 180 | 97% | 838.28 | 417 / 430 |
| intestine | 99% | 3467.63 | 953 / 966 | 94% | 605.12 | 493 / 527 |
| breast | 100% | 6961.69 | 459 / 459 | 89% | 403.31 | 999 / 1118 |
| uterus | 100% | 6647.39 | 170 / 170 | 81% | 339.94 | 374 / 459 |
| lung | 99% | 4004.16 | 574 / 578 | 81% | 223.89 | 933 / 1155 |
| esophagus | 95% | 3055.66 | 1378 / 1445 | 77% | 192.87 | 140 / 183 |
| stomach | 78% | 1836.89 | 280 / 359 | 88% | 495.16 | 253 / 286 |
| bladder | 100% | 3390.48 | 21 / 21 | 64% | 325.82 | 324 / 504 |
| skin | 92% | 2713.01 | 1663 / 1809 | 65% | 239.82 | 308 / 472 |
| kidney | 98% | 5109.99 | 87 / 89 | 53% | 105.52 | 474 / 901 |
| thymus | 100% | 4804.58 | 650 / 653 | 35% | 55.91 | 214 / 605 |
| prostate | 95% | 3175.17 | 233 / 245 | 39% | 63.21 | 197 / 502 |
| pancreas | 29% | 388.79 | 95 / 328 | 80% | 203.16 | 143 / 178 |
| adipose | 100% | 8073.66 | 1204 / 1204 | 0% | 0 | 0 / 0 |
| peripheral blood | 100% | 16934.82 | 929 / 929 | 0% | 0 | 0 / 0 |
| spleen | 100% | 10220.98 | 241 / 241 | 0% | 0 | 0 / 0 |
| heart | 98% | 3437.38 | 848 / 861 | 0% | 0 | 0 / 0 |
| adrenal gland | 82% | 1598.47 | 212 / 258 | 15% | 21.01 | 34 / 230 |
| blood vessel | 94% | 3268.67 | 1251 / 1335 | 0% | 0 | 0 / 0 |
| lymph node | 0% | 0 | 0 / 0 | 90% | 218.50 | 26 / 29 |
| liver | 69% | 1351.55 | 155 / 226 | 18% | 39.26 | 74 / 406 |
| tonsil | 0% | 0 | 0 / 0 | 87% | 282.51 | 39 / 45 |
| brain | 52% | 1108.85 | 1382 / 2642 | 22% | 37.56 | 152 / 705 |
| muscle | 66% | 1197.34 | 526 / 803 | 0% | 0 | 0 / 0 |
| eye | 0% | 0 | 0 / 0 | 36% | 95.35 | 29 / 80 |
| abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
| GO_0009615 | Biological process | response to virus |
| GO_0051607 | Biological process | defense response to virus |
| GO_0030336 | Biological process | negative regulation of cell migration |
| GO_0008285 | Biological process | negative regulation of cell population proliferation |
| GO_0060337 | Biological process | type I interferon-mediated signaling pathway |
| GO_0001503 | Biological process | ossification |
| GO_0035455 | Biological process | response to interferon-alpha |
| GO_0045071 | Biological process | negative regulation of viral genome replication |
| GO_0034341 | Biological process | response to type II interferon |
| GO_0046597 | Biological process | negative regulation of viral entry into host cell |
| GO_0045669 | Biological process | positive regulation of osteoblast differentiation |
| GO_0035456 | Biological process | response to interferon-beta |
| GO_0007166 | Biological process | cell surface receptor signaling pathway |
| GO_0032991 | Cellular component | protein-containing complex |
| GO_0005886 | Cellular component | plasma membrane |
| GO_0005765 | Cellular component | lysosomal membrane |
| GO_0016020 | Cellular component | membrane |
| GO_0005515 | Molecular function | protein binding |
| Gene name | IFITM1 |
| Protein name | Interferon-induced transmembrane protein 1 (Dispanin subfamily A member 2a) (DSPA2a) (Interferon-induced protein 17) (Interferon-inducible protein 9-27) (Leu-13 antigen) (CD antigen CD225) Interferon induced transmembrane protein 1 |
| Synonyms | CD225 IFI17 |
| Description | FUNCTION: IFN-induced antiviral protein which inhibits the entry of viruses to the host cell cytoplasm, permitting endocytosis, but preventing subsequent viral fusion and release of viral contents into the cytosol. Active against multiple viruses, including influenza A virus, SARS coronaviruses (SARS-CoV and SARS-CoV-2), Marburg virus (MARV), Ebola virus (EBOV), Dengue virus (DNV), West Nile virus (WNV), human immunodeficiency virus type 1 (HIV-1) and hepatitis C virus (HCV) . Can inhibit: influenza virus hemagglutinin protein-mediated viral entry, MARV and EBOV GP1,2-mediated viral entry and SARS-CoV and SARS-CoV-2 S protein-mediated viral entry. Also implicated in cell adhesion and control of cell growth and migration . Inhibits SARS-CoV-2 S protein-mediated syncytia formation . Plays a key role in the antiproliferative action of IFN-gamma either by inhibiting the ERK activation or by arresting cell growth in G1 phase in a p53-dependent manner. Acts as a positive regulator of osteoblast differentiation. In hepatocytes, IFITM proteins act in a coordinated manner to restrict HCV infection by targeting the endocytosed HCV virion for lysosomal degradation . IFITM2 and IFITM3 display anti-HCV activity that may complement the anti-HCV activity of IFITM1 by inhibiting the late stages of HCV entry, possibly in a coordinated manner by trapping the virion in the endosomal pathway and targeting it for degradation at the lysosome . . |
| Accessions | ENST00000679765.1 ENST00000679353.1 P13164 ENST00000680855.1 ENST00000680588.1 ENST00000681426.1 ENST00000679982.1 A0A7P0T921 A0A7P0T9N0 ENST00000680342.1 A0A7P0TAH2 A0A7P0TAW0 A0A7P0TAF0 A0A7P0T8E0 A0A7P0TA40 ENST00000681577.1 ENST00000679380.1 ENST00000680870.1 ENST00000681821.1 ENST00000680299.1 ENST00000680938.1 ENST00000681702.1 A0A7P0T8C2 A0A7P0TB03 ENST00000328221.5 ENST00000680310.1 ENST00000680802.1 ENST00000681350.1 ENST00000681761.1 ENST00000680699.1 ENST00000680696.1 ENST00000408968.4 ENST00000681111.1 ENST00000681938.1 ENST00000528780.5 A0A7P0Z452 ENST00000681180.1 |
